Unicycive Therapeutics (NASDAQ:UNCY) Rating Lowered to Sell at Wall Street Zen

Unicycive Therapeutics (NASDAQ:UNCY) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Other equities analysts have also issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Unicycive Therapeutics in a report on Wednesday, October 8th. Benchmark raised their target price on Unicycive Therapeutics to $21.00 and gave the company a “speculative buy” rating in a report on Monday, September 15th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $57.00.

Unicycive Therapeutics Price Performance

NASDAQ UNCY opened at $5.13 on Friday. Unicycive Therapeutics has a fifty-two week low of $3.71 and a fifty-two week high of $11.00. The stock’s 50-day moving average is $4.35 and its two-hundred day moving average is $5.20. The firm has a market cap of $90.61 million, a P/E ratio of -1.25 and a beta of 1.86.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its earnings results on Thursday, August 14th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.70) by $0.18. On average, equities analysts expect that Unicycive Therapeutics will post -0.23 EPS for the current year.

Institutional Investors Weigh In On Unicycive Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vivo Capital LLC grew its position in shares of Unicycive Therapeutics by 14.0% in the first quarter. Vivo Capital LLC now owns 11,370,152 shares of the company’s stock valued at $6,537,000 after purchasing an additional 1,400,000 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Unicycive Therapeutics by 11,698.4% in the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after purchasing an additional 21,525 shares during the last quarter. Finally, Lazard Asset Management LLC acquired a new stake in shares of Unicycive Therapeutics in the second quarter valued at about $55,000. 40.42% of the stock is owned by institutional investors and hedge funds.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.